Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IAT-S2
- Development stage
- Preclinical
- Lead developer
- InterAct Therapeutics
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
IAT-S2 is an adeno-associated virus serotype 8 (AAV8)-based gene therapy designed to treat breast cancer-derived liver metastases (BCLM). Developed by InterAct Therapeutics, the therapy targets hepatocytes to modulate the liver microenvironment, restoring hepatocyte fitness and reversing the cell competition mechanism by which metastatic breast cancer cells colonize and expand in the liver. By delivering a therapeutic transgene directly to hepatocytes, IAT-S2 aims to prevent metastatic colonization and suppress metastatic outgrowth, offering a one-time, disease-modifying treatment for liver-dominant metastatic breast cancer.
Beyond the preview
Go deeper on IAT-S2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAT-S2.